Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 120 participants.
Also called NCT04702490
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 120 participants
- Sponsor
- Metacrine, Inc.
- Registry
-
NCT04702490
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Unknown status
Technical summary
Registry record NCT04702490. Randomized; quadruple masking; primary purpose treatment. Start 2020-12-15 (actual); primary completion 2022-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
- Condition
- NASH
- Condition
- NASH - Nonalcoholic Steatohepatitis
- Condition
- Type 2 Diabetes
- Condition
- Diabetes Type 2
- Condition
- Diabetes
- Condition
- Fatty Liver
- Condition
- Fatty Liver, Nonalcoholic
- Condition
- NAFLD
- Intervention (Drug)
- MET409 Active
- Intervention (Drug)
- MET409 Placebo
- Intervention (Drug)
- Empagliflozin
- Lead sponsor
- Metacrine, Inc.
Record details
- Record id
cardio:ct-nct04702490- Content hash
483a54afb3568f23f5998c06d800df1017e8faf7de6fc47092091cf2ae897936